Jens Hennecke Joins Delenex Therapeutics AG
News Nov 13, 2013
Delenex Therapeutics AG has announced that it has engaged Jens Hennecke, PhD, as Business and Corporate Development Advisor.
Dr. Jens Hennecke (46) has a strong track record in business development, corporate development and licensing. He brings extensive experience in the negotiation and closing of corporate alliances.
Prior to joining Delenex and building his own business development advisory franchise, he held the position of Senior Vice President Business Development at Micromet, Inc. where he played a key role in establishing partnerships with major pharma companies, as well as in Micromet’s acquisition by Amgen in 2012.
Dr. Hennecke holds a B.Sc. in biology from the University of Göttingen, Germany, and a Ph.D. from the ETH Zurich, Switzerland.
Dr. Thomas Hecht, Executive Chairman of Delenex mentioned, “We are pleased and proud to have attracted Jens with his international experience and strong business development and licensing background. We are convinced that Jens will add to the success of Delenex and spearhead our business development activities to add new partnerships.”
“I am very much looking forward to working with Delenex,” said Dr. Jens Hennecke. “Delenex has a strong pipeline of PENTRA®Bodies and advanced clinical projects, including topical treatments of dermatologic diseases. This provides for significant partnering opportunities beyond Novartis’ exclusive use of the platform for ophthalmic diseases.”
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
New Way Found to Boost Immunity in Fighting Cancer and InfectionsNews
Researchers have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Brillouin Microscopy: Emerging Tool for Probing Mechanical Properties of Living Cells
Jan 17 - Jan 19, 2018